The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-γ activating capacity on plasma 8-isoprostane prostaglandin F2a levels

Archives of Medical Science

Volumn 9, Issue 1, 2013, Pages 172-176

  Rizos, Christos V ^a   Liberopoulos, Evangelos N ^a   Tellis, Constantinos C ^b   Tselepis, Alexandros D ^b   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Irbesartan; Olmesartan; Oxidative stress; Rosuvastatin; Telmisartan

Indexed keywords

8 ISOPROSTANE PROSTAGLANDIN F2 ALPHA; GLUCOSE; IRBESARTAN; OLMESARTAN; PROSTAGLANDIN F2 ALPHA; ROSUVASTATIN; TELMISARTAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DRUG MECHANISM; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

EID: 84874911039     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2013.33357     Document Type: Article

References (24)

1. Katsiki N, Mikhailidis DP, Athyros VG, Hatzitolios AI, Karagiannis A, Banach M. Are we getting to lipid targets in real life? Arch Med Sci 2010; 6: 639-41.
2. Athyros VG, Hatzitolios AI, Karagiannis A, et al. Improving the imPlemEntation of cuRrent guidelines for the mAna - gement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011; 7: 984-92.
3. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 29-38.
4. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchel - li GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004; 256: 308-15.
5. Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 2000; 32: 377-85.
6. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidative stress in vivo: an overview. Bio - markers 2005; 10 Suppl 1: S10-23.
7. Kostapanos MS, Spyrou AT, Tellis CC, et al. Ezetimibe treatment lowers indicators of oxidative stress in hyper - cholesterolemic subjects with high oxidative stress. Lipids 2011; 46: 341-8.
8. Davies SS, Roberts LJ 2nd. F2-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med 2011; 50: 559-66.
9. Yilmaz MI, Baykal Y, Kilic M, et al. Effects of statins on oxidative stress. Biol Trace Elem Res 2004; 98: 119-27.
10. Agouridis AP, Tsimihodimos V, Filippatos TD, et al. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother 2011; 12: 2605-11.
11. Da Ros R, Assaloni R, Ceriello A. The preventive antioxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet Med 2004; 21: 1249-52.
12. Hwang J, Kleinhenz DJ, Rupnow HL, et al. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Vascul Pharmacol 2007; 46: 456-62.
13. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor anta - gonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
14. Rizos CV, Milionis HJ, Kostapanos MS, et al. Effects of rosuvastatin combined with olmesartan, irbesartan, r telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. Clin Ther 2010; 32: 492-505.
15. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASHSodium Collaborative Research Group. N Engl J Med 2001; 344: 3-10.
16. Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006; 48: 752-60.
17. Tycinska AM, Janica J, Mroczko B, et al. Hypotensive effect of atorvastatin in hypertensive patients: the association among flow-mediated dilation, oxidative stress and endothelial dysfunction. Arch Med Sci 2011; 7: 955-62.
18. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dosedependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22: 1845-51.
19. Landmesser U, Cai H, Dikalov S, et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002; 40: 511-5.
20. Sola S, Mir MQ, Cheema FA, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111: 343-8.
21. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135-40.
22. Rizos EC, Spyrou A, Liberopoulos EN, et al. Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. Open Cardiovasc Med J 2007; 1: 22-6.
23. Galle J, Schwedhelm E, Pinnetti S, Boger RH, Wanner C. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23: 3174-83.
24. Lazich I, Sarafidis P, de Guzman E, Patel A, Oliva R, Bak - ris G. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab 2012; 14: 181-6.